Proactive Investors - Run By Investors For Investors

Allergy Therapeutics strengthens clinical research team with senior appointments

Pieter-Jan de Kam joins as clinical director, while Simon Piggott will become head of clinical science
picture of handshake
Allergy is strengthening its clnical research team

Allergy Therapeutics plc (LON:AGY) has strengthened its clinical research team with two senior appointments.

Pieter-Jan de Kam joins as clinical director, while Simon Piggott will become head of clinical science.

At his previous firm, Dutch firm HAL Allergy, de Kam was in charge of clinical development for pollen and dust mites, two key product development areas for Allergy.

Allergy Therapeutics revenues rise as hay fever portfolio cleans up

Piggot, meanwhile, has significant experience of taking respiratory development programs through Phase I to IV trials and will be responsible for the delivery of Allergy's clinical strategy and products pipeline.

In addition, Tim Higenbottam has been appointed to the position of senior pharmaceutical physician and will focus on the US regulatory process.

Murray Skinner, Allergy’s chief scientific officer of Allergy Therapeutics, said the trio’s vast experience and expert knowledge was ideal to help bring new and convenient into the allergy immunotherapy market."

View full AGY profile View Profile

Allergy Therapeutics PLC Timeline

Related Articles

Callitas CEO James Thompson
July 20 2018
CannaStrips will generate near-term revenue, while the company’s blue-sky pharmaceutical assets and orphan drug are solid, long-term plays
Woman sneezing
September 27 2018
"We look forward to the exciting developments in our early pipeline planned for 2019, and we expect to continue to grow our European business while progressing towards US and German registration for our lead products," said company chairman, Peter Jensen
porcupine
November 30 2018
It’s been a tricky period for Redx, but it has come through it with a promising pipeline, cash in the bank and AstraZeneca’s former UK boss as its new chief executive

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use